Abstract
Background: Oral cancer is a malignant tumor with a high impact and poor prognosis. Naringenin, a flavonoid found in citrus fruits and its anti-inflammatory and antioxidant properties offer potential therapeutic benefits. However, limited studies have been conducted on the impact of naringenin on human tongue carcinoma CAL-27 cells. This study aims to elucidate the correlation between naringenin and tongue cancer, thereby identifying a potential therapeutic candidate for drug intervention against tongue cancer.
Methods: The effect of naringenin on the apoptosis of CAL-27 cells and its mechanism were studied by cell counting kit-8, mitochondrial membrane potential assay with JC-1, Annexin V-- FITC apoptosis detection, cell cycle, and apoptosis analysis, Reactive Oxygen Species assay and Western blot.
Results: The results showed that naringenin significantly induced apoptosis in CAL-27 cells in a dose-dependent manner. Mechanistically, naringenin-induced apoptosis was mediated through the upregulation of Bid and downregulation of Bcl-xl, which led to increased generation of ROS.
Conclusion: The findings suggested that naringenin may represent a promising candidate for the treatment of oral cancer by inducing apoptotic cell death via modulation of the Bid and Bcl-xl signaling pathways.
Keywords: Naringenin, oral cancer, ROS, Bid, Bcl-xl, signaling pathway, apoptosis.
[http://dx.doi.org/10.1038/s41421-023-00532-4] [PMID: 36914617]
[http://dx.doi.org/10.1186/s40001-022-00835-4] [PMID: 36209263]
[http://dx.doi.org/10.1038/s41598-019-38575-x] [PMID: 30765854]
[http://dx.doi.org/10.1016/S1470-2045(21)00136-4] [PMID: 33989559]
[http://dx.doi.org/10.3390/ijms232113629] [PMID: 36362414]
[http://dx.doi.org/10.1186/s13046-022-02409-y] [PMID: 35681210]
[http://dx.doi.org/10.3390/nu14122413] [PMID: 35745143]
[http://dx.doi.org/10.3389/fphar.2022.906746]
[http://dx.doi.org/10.1155/2022/5992436]
[http://dx.doi.org/10.1007/s00262-023-03452-0] [PMID: 37149552]
[http://dx.doi.org/10.1016/j.phymed.2022.154401]
[http://dx.doi.org/10.1007/s00262-022-03149-w] [PMID: 35044489]
[http://dx.doi.org/10.1007/s12011-022-03369-2] [PMID: 35896885]
[http://dx.doi.org/10.1039/D1RA08658H]
[http://dx.doi.org/10.1007/s11033-022-07418-w] [PMID: 35412176]
[http://dx.doi.org/10.1021/acsomega.2c07575]
[http://dx.doi.org/10.1016/j.crfs.2022.09.016]
[http://dx.doi.org/10.3390/ijms22073701] [PMID: 33918172]
[http://dx.doi.org/10.1007/978-1-0716-1278-1_17]
[http://dx.doi.org/10.1002/brb3.558] [PMID: 28127506]
[http://dx.doi.org/10.7554/eLife.73511]
[http://dx.doi.org/10.1002/hed.26464] [PMID: 32914472]
[http://dx.doi.org/10.1016/j.lfs.2022.120752]
[http://dx.doi.org/10.3390/biomedicines10071686] [PMID: 35884991]
[http://dx.doi.org/10.1016/j.biopha.2021.112442]
[http://dx.doi.org/10.3389/fphar.2018.00866]
[PMID: 9493953]
[http://dx.doi.org/10.1016/j.taap.2018.06.003]
[http://dx.doi.org/10.1016/j.omtn.2017.09.004]
[http://dx.doi.org/10.7150/ijms.50080] [PMID: 33437206]
[http://dx.doi.org/10.3390/ijms23073691] [PMID: 35409052]
[http://dx.doi.org/10.1002/prot.26238] [PMID: 34528298]
[http://dx.doi.org/10.1016/j.bbrc.2017.06.190] [PMID: 28676391]